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Introduction: Recently,novel allergometric techniques
allow to test inhalants,food,and also drugs by speciﬁc
in vitro assays. A ﬂow cytometry technique based on
the search of sulphidoleukotrienes LCT4, LTD4 and LTE4
released by basophils stimulated in vitro by IL-3 in
presence of the examined antigens (cellular antigen stim-
ulation test,or CAST), has a 80—90% sensitivity-speciﬁcity
rate,and becomes particularly useful when prick tests are
not applicable, and allergic reactions are not mediated
by allergen-speciﬁc IgE immunoglobulins.Methods-Results:
During the past three years, 13 HIV-infected subjects (eight
females and ﬁve males, aged 37—52 years),underwent a
standardized, speciﬁc in vitro cellular antigen stimulation
test (CAST),due to serious cutaneous (six cases),systemic
(two patients), and combined cutaneous-systemic hyper-
sensitivity reactions (ﬁve subjects),apparently not elicited
by the introduction of abacavir and nevirapine (which are
the antiretroviral agents burdened by the greatest fre-
quency of expected early allergic reactions,mediated by
already recognized pathogenetic mechanisms). Based on the
results of CAST testing, an allergic intolerance to ritonavir
(six cases), lopinavir,nelﬁnavir, and didanosine (three cases
each), saquinavir and lamivudine (two cases), and fosam-
prenavir,zidovudine, zalcitabine, stavudine, and efavirenz
(one case each), was documented: in 10 cases out of 13
(76.9.5%) multiple intolerances were detected. A perfect
relationship was documented between the results of CAST
testing and the panel of combined antiretroviral compounds
recently experienced by each allergic patient,and a CAST-
based elimination of in vitro allergenic molecules allowed a
rapid introduction of another effective antiretroviral com-
bination.
Conclusions: Adverse events to antiretroviral drugs are
quite frequent among HIV-infected patients, compared
with the general population. Further,controlled studies are
needed to implement in vitro allergometric testing in
patients treated for HIV infection,who are exposed to unpre-
dictable drug intolerance reactions. In fact,HIV-infected
subjects may suffer from frequent allergic drug reactions
which may be difﬁcult to be systematically recognized (due
to the frequent,multiple concurrent pharmacotherapy, and
the combined antiretroviral therapy itself).
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HIV Genotypes and Patterns of Drug Resistance in Patients
Failing HAART in a University Hospital Clinic
G. Revathi ∗, M. Bholla, P. Wangai, R. Harania, P. Ojwang
The Aga Khan University Hospital, Nairobi, Kenya
Background: HAART strategies yield excellent results in
drug na¨ıve patients starting ﬁrst-line treatment. Yet, data
from clinical cohorts indicate drug resistance emerging as
a consequence of toxicity, drug interactions or adherence
problems leading to sub-optimal serum drug concentrations.
The Aga Khan University Hospital, Nairobi, has compre-
hensive HIV care services since 2003 at the one stop clinic.
About 500 patients are on current follow-up by standard
international protocols.
Methods: Over one year, 38 patients failed ART and
were referred to the laboratory for resistance testing per-
formed by population sequencing technique using VIRASEQ
(Abbott) by manufacturer’s protocol. All clinical details
were recorded during sample collection.
Results: All patients belonged to a high socioeconomic
group with corporate health insurance cover and claimed
excellent drug adherence.
Patient age ranged from 6 to 57 years with a median
of 38 years. CD4 counts ranged from 12 to 450 with a
median of 135. Viral loads ranged from 2100 to 13 mil-
lion with a median of 140,000. 82% (31/38) of patients had
multiple hospital admissions indicating 2 to 5 episodes of
opportunistic infections of which TB (14 patients), PCP (11
patients), Cryptococcosis (10 patients) and Salmonellosis (8
patients) were most common. 4 patients had 3 simultane-
ous opportunistic infections. 6 patients had 2 simultaneous
opportunistic infections. Only 8 patients were on second-line
HAART which included boosted PI. 9 patients used ARVs for
over 10 years. A, D and CRFO1 were predominant subtypes.
Major NRTI/NNRTI mutations were seen in 80% of patients
while major PI mutations were seen in 8% of patients. High-
level resistance was seen to Tenofovir in 8% of patients,
Nevirapine, Efaverenz, 3TC & FTC in 80% of patients and
AZT in 29% of patients.
Conclusions: In the long run, high-level multiple resis-
tance is inevitable in patients on HAART, with serious




Multi-Pronged Strategy Greatly Enhances Enrollment of
HIV Positive Children Into HIV Care and Treatment: Expe-
rience from Uganda
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Uganda
Background: Although Uganda had successfully rolled out
Antiretroviral therapy (ART) in HIV-infected adults, enroll-
ment of children aged less than 15 years onto ART had
generally been very slow. However, the implementation of a
multi-pronged strategy for scaling-up pediatric HIV care has
